Skip to main content
Clinical Trials/NCT06691633
NCT06691633
Completed
Phase 4

Postoperative Pain and Analgesic Requirements After Preoperative Methadone for Primary Total Knee Arthroplasty, a Prospective, Randomized Study

University of Louisville1 site in 1 country150 target enrollmentFebruary 19, 2024

Overview

Phase
Phase 4
Intervention
Preoperative Methadone
Conditions
Osteoarthritis (OA) of the Knee
Sponsor
University of Louisville
Enrollment
150
Locations
1
Primary Endpoint
Daily Opioid Use
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this prospective, randomized study is to compare the outcomes of two cohorts of patients undergoing primary Total Knee Arthroplasty (TKA) and to determine whether a single dose of methadone administered preoperatively is effective at reducing postoperative opioid usage and postoperative pain versus a control group of patients receiving standard intraoperative opioids only for primary TKA.

The main questions it aims to answer are:

  • What is the efficacy of a single preoperative dose of methadone in reducing opioid consumption and postoperative pain in primary total knee arthroplasty?
  • Will the study results demonstrate the effectiveness and safety of a single preoperative dose of methadone (10 mg) in primary total knee arthroplasty in reducing postoperative opioid usage while maintaining a similar or better level of pain control when compared to a standard pain control regimen? Researchers will compare Methadone to a standard pain control regimen (Oxycodone) to see if Methadone is equivalent or more effective at reducing opioid consumption and postoperative pain in primary total knee arthroplasty

Participants will:

  • be randomized into one of two groups
  • undergo a primary TKA
  • complete a tracking sheet documenting daily pain medicine usage and VAS pain level for the first 14 days following the TKA
  • return to office at 2 weeks and 6 weeks postop for follow-up
  • complete additional questionnaires at 2 weeks and 6 weeks postop
Registry
clinicaltrials.gov
Start Date
February 19, 2024
End Date
October 18, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Arthur Malkani

Orthopedic Surgeon

University of Louisville

Eligibility Criteria

Inclusion Criteria

  • Patient age is 21-89 at time of surgery
  • Patient is scheduled to undergo a unilateral primary TKA, secondary to osteoarthritis
  • Patient agrees to participate as a study subject and signs the Informed Consent and Research Authorization document
  • Patient is able to read and speak English.

Exclusion Criteria

  • Patient is under the age of 21
  • Patient's primary diagnosis is not osteoarthritis
  • Patient is unable to read and speak English
  • History of liver or kidney disease,
  • Known or suspected GI obstruction
  • Hypersensitivity to methadone
  • Patients with significant respiratory depression
  • Pregnant or nursing females

Arms & Interventions

Methadone Group

Participant receives a one-time preoperative dose of 10 mg of methadone

Intervention: Preoperative Methadone

Oxycodone Group

participant receives a one-time preoperative dose of 10 mg of oral oxycodone

Intervention: Preoperative Oxycodone

Outcomes

Primary Outcomes

Daily Opioid Use

Time Frame: 2 weeks

Daily Opioid Use as measured in MME recorded daily for the first two weeks following TKA

Total opioid usage over two weeks

Time Frame: 2 weeks

total daily opioid usage (as measured in MME) during the first 14 days following TKA

Visual Analogue Scale pain score

Time Frame: 2 weeks

Visual Analogue Scale knee pain score (minimum value: 0, maximum value: 10). Higher scores equate to a worse outcome (a score of zero = pain free).

Secondary Outcomes

  • Discharge location(2 weeks)
  • Hospital Length of Stay(Up to 2 weeks)
  • Two and six-week narcotic refill(6 weeks)
  • Knee Injury and Osteoarthritis Outcome Score, Joint Replacement score(preoperatively and 6 weeks (± 2 weeks) postoperatively)
  • ROM(preoperatively, 2 weeks and 6 weeks (± 2 weeks) postoperatively)

Study Sites (1)

Loading locations...

Similar Trials